Merck & Co shares jumped in Tuesday’s session, with MRK closing at $113.37, up $3.10 (2.81%) on the day, as investors digested the company’s fourth-quarter and full-year 2025 results alongside a steady outlook for 2026.
The stock traded as high as $113.89 and as low as $109.95 during the session, with the move lifting MRK back near its recent highs as markets reacted to revenue strength in oncology and animal health.
Market Snapshot — Merck (NYSE: MRK)
Last close
$113.37
Day change
+$3.10 (+2.81%)
Day range
$109.95 – $113.89
Open
$110.12
Market cap
$28.14T (as shown)
P/E ratio
14.99
Dividend yield
3.00%
52-week range
$73.31 – $113.89
Merck reported worldwide sales of $16.4 billion in the fourth quarter and full-year 2025 worldwide sales of $65.0 billion, reflecting continued demand for its core franchises and increasing contributions from newer launches.
Earnings were also in focus. Merck posted Q4 GAAP EPS of $1.19 and Q4 non-GAAP EPS of $2.04. For the full year, the company reported GAAP EPS of $7.28 and non-GAAP EPS of $8.98.
The biggest revenue engine remained KEYTRUDA. Merck’s 2025 product mix continued to lean on oncology strength, while animal health added a second pillar of growth and helped balance performance across the portfolio.
Management framed 2025 as a year of execution and portfolio-building. CEO Rob Davis said the business benefited from demand across the innovative portfolio, contributions from new launches in cardiometabolic and respiratory as well as vaccines, and strong performance in animal health, while pointing to momentum from business development.
Looking ahead, Merck guided for full-year 2026 worldwide sales between $65.5 billion and $67.0 billion, signalling expectations for modest top-line growth as the company continues to invest in research and commercial expansion.
On earnings, Merck forecast 2026 non-GAAP EPS of $5.00 to $5.15, reflecting a year that is expected to include continued investment and integration work following recent deals, even as the company aims to keep growth drivers moving in oncology and beyond.
With MRK now trading at a mid-teens earnings multiple and offering an income component through its dividend, the stock’s move suggests investors are rewarding visibility and execution, while keeping a close eye on pipeline progress and the pace of contribution from newer launches.
Merck detailed the quarter and full-year performance — including sales, earnings and its 2026 outlook — in its Q4 and full-year 2025 financial results update.
